Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Current Opinion in Immunology Année : 2021

Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies

Résumé

Sustained transcriptional activation of the aryl hydrocarbon receptor (AhR) promotes tumour growth and impairs the immune defence, at least for cutaneous melanoma and glioma. AhR ligands are produced by the tumour microenvironment (TME) and by the tumour itself (intracrine). The recent identification of interleukin-4-induced-1 (IL4I1), a parallel pathway to indoleamine 2 3-dioxygenase 1 (IDO1)/ tryptophan 2,3-dioxygenase (TDO), and its ability to generate AhR ligands, confirms that a complete inhibition of AhR ligand production might be difficult to reach. Here, we have focused on recent discoveries explaining the large varieties of AhR ligands and the functional consequences in terms of cancer cell plasticity and consecutive therapy resistance. We also examined therapeutic strategies targeting the AhR signalling pathway and their possible adverse effects. Since the end of 2019, two phase I clinical trials have investigated the ability of the AhR antagonist to ’reset’ the immune system and re-sensitize the cancer cells to therapies by preventing their dedifferentiation.

Domaines

Cancer Immunologie
Fichier principal
Vignette du fichier
Leclerc-Gilot - 2021 - Detrimental activation of AhR pathway in cancer.pdf (1.68 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03129154 , version 1 (22-02-2021)

Identifiants

Citer

Delphine Leclerc, Ananda Christina Staats Pires, Gilles J Guillemin, David Gilot. Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies. Current Opinion in Immunology, 2021, 70, pp.15-26. ⟨10.1016/j.coi.2020.12.003⟩. ⟨hal-03129154⟩
576 Consultations
1013 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More